《美银BofA：欧盟医疗技术与医疗服务行业研究：精准医疗回归；前景可期-251022（英文版）（40页）.pdf》由会员分享，可在线阅读，更多相关《美银BofA：欧盟医疗技术与医疗服务行业研究：精准医疗回归；前景可期-251022（英文版）（40页）.pdf（40页珍藏版）》请在三个皮匠报告上搜索。

1、 Employed by a non-US affiliate of BofAS and is not registered/qualified as a research analyst under the FINRA rules.Refer to Other Important Disclosures for information on certain BofA Securities entities that take responsibility for the information herein in particular jurisdictions.BofA Securitie

2、s does and seeks to do business with issuers covered in its research reports.As a result,investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report.Investors should consider this report as only a single factor in making their investment d

3、ecision.Refer to important disclosures on page 37 to 40.Analyst Certification on page 36.Price Objective Basis/Risk on page 36.12889509 EU Medtech&Healthcare Services A Dose of Precision:Radiopharmaceuticals are back and here to stay Estimate Change Radiopharmaceuticals The great comeback Radiopharm

4、aceuticals are bioactive molecules tagged with a radionuclide,used for either SPECT or PET scan.The radionuclide is selected for the application at hand(diagnosis or therapy).Major discoveries in the field were made in the 1960s,but the first antibody-directed radiotherapeutics didnt live up to comm

5、ercial usage due to an unfavourable risk/benefit.This changed with the approval of PLUVICTO in 2022.This report provides insights for readers about radiotracers and related imaging equipment.$30bn radiopharma market fuelled by PSMA blockbusters Following the rebirth of theranostics(pairing radiotrac

6、er and radiotherapeutic)with PLUVICTO,other related PSMA-based tracers have reignited interest in the sector and expanded the field of radiopharmaceuticals to an era of precision cancer therapy by delivering the nuclear therapy directly to cancer lesions.Supported by a strong Pharma R&D pipeline and